Proactive Investors
08 Jun 2026, 08:25 UTC · 5h ago
Coiled Therapeutics strengthens its scientific bench
Proactive Investors
08 Jun 2026, 08:25 UTC · 5h ago
Story key points
3 claims · impact-rated
Thor Explorations reported Q1 revenue of $74.3 million and net income of $46.7 million, driven by a gold price of $4,820 per ounce. — Strong net income growth and a significantly elevated gold price suggest high profitability and positive momentum for the company.
+0.60Coiled Therapeutics appointed Professor Ozgur Sahin, a foundational patent inventor for AO-252, as a scientific advisor. — Securing a leading authority on the drug's target biology reduces scientific risk and adds credibility to the lead candidate.
+0.30Coiled Therapeutics' lead candidate AO-252 is moving toward dose expansion cohorts and the start of a combination therapy protocol in 2026. — Advancement toward clinical milestones is a positive catalyst for biotech valuations, though it remains early-stage (Phase I).
+0.20Ticker attribution
Continue reading
6 related stories
Top 1 mover · tap to explore
Model heads
The company reported strong first quarter financial results with significant increases in revenue and net income.
The company strengthened its scientific expertise by appointing a leading authority as an advisor for its lead drug candidate.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
TheNewswire
2h ago
